Step Therapy

Step therapy, sometimes called “fail first,” is a tool insurers use to manage prescription drug costs. Before the plan will pay for a higher-cost medication, you have to try one or more lower-cost alternatives. If the cheaper drug does not work or causes intolerable side effects, the plan moves you up the ladder, “stepping” toward the more expensive option.

It is not a denial of care. It is a sequencing rule. But it can delay access to the drug your doctor wanted you to start with, sometimes by weeks or months.

How a step protocol typically looks

A plan’s step therapy policy for, say, a biologic for rheumatoid arthritis might look like this:

1. Step 1: try a generic disease-modifying antirheumatic drug (DMARD) such as methotrexate for a defined period (often 3 months).
2. Step 2: if step 1 fails or causes side effects, try a preferred biologic on the formulary.
3. Step 3: if step 2 fails or causes side effects, the plan will approve the non-preferred biologic your doctor originally prescribed.

The exact sequence is set by the plan, not by your doctor. It is written into the formulary and is part of how prescription drug tiers are managed.

Where step therapy commonly applies

You are most likely to run into step therapy on:

• Biologics for autoimmune conditions: rheumatoid arthritis, psoriasis, Crohn’s disease, ulcerative colitis.
• Specialty oncology drugs: certain targeted therapies and second-line chemotherapy regimens.
• High-cost migraine treatments: CGRP inhibitors after failing triptans and beta-blockers.
• PCSK9 inhibitors for cholesterol: after failing statins at maximum tolerated dose.
• Branded drugs with generic equivalents: most plans require the generic first.

It is uncommon on routine generics, common cardiovascular drugs, and most antibiotics.

You can appeal

Step therapy is not absolute. If your doctor documents that the required first-step drug is medically inappropriate for you, you can file an appeal. Strong grounds for appeal include:

• You have already tried the lower-step drug in the past and it failed or caused side effects.
• The lower-step drug is contraindicated because of another condition you have.
• The required wait would cause harm given your specific diagnosis.
• The lower-step drug has a known interaction with another medication you must keep taking.

The appeal goes through the same process as a claims appeal or prior authorization denial. Get the appeal letter in writing from your prescriber, attach the supporting medical records, and submit it through the plan’s published appeals channel. Most plans must respond within 72 hours for urgent cases and 30 days for standard cases.

Why insurers use it

The economic case is straightforward. Generic and lower-tier drugs often work for a large share of patients, and they cost a fraction of the branded or specialty alternative. By requiring the cheaper drug first, insurers reduce total drug spending and pass some of those savings into lower premiums. The clinical case is mixed: for some conditions step therapy delays effective treatment, which is why state laws and federal Medicare rules increasingly carve out exceptions for cancer, mental health, and certain chronic conditions.

Example

A 50-year-old in North Carolina with newly diagnosed rheumatoid arthritis is prescribed adalimumab (Humira) by their rheumatologist. The Marketplace plan’s step therapy policy requires 3 months of methotrexate first. The rheumatologist documents that the patient already tried methotrexate two years ago for an autoimmune condition and developed liver enzyme elevation, and files an appeal with the lab records. The plan approves adalimumab within 10 days, skipping step 1.

Related terms

• Prior Authorization
• Formulary
• Prescription Drug Tier
• Claims Appeal

Run the calculator to compare plans by drug coverage and step therapy policies.